Skip to content

Mechanisms Underlying Metabolic Syndrome in Obesity

Mechanisms Underlying Metabolic Syndrome in Obesity

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00579813
Enrollment
70
Registered
2007-12-24
Start date
2005-04-30
Completion date
2011-01-31
Last updated
2017-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Metabolic Syndrome, Prediabetes

Keywords

obesity, inflammation, diabetes

Brief summary

The purpose of this study is to better understand the link between obesity and diabetes or pre-diabetes.

Detailed description

Obesity is the most common and powerful force for creating insulin resistance and metabolic syndrome, however, the molecular basis of this association is not well understood. In this proposal, three independently funded researchers-Philip Kern, MD a clinical investigator, and Charlotte Peterson, PhD and Robert McGehee, PhD, with significant experience in muscle and adipocyte biology, respectively-will formalize a collaborative effort as a natural extension of previous work and shared interests in the fields of obesity, insulin resistance, and tissue lipid accumulation. Our overall hypothesis is that insulin resistance in humans stems largely from ectopic accumulation of intramyocellular lipid (IMCL) during the development of obesity. Further, we hypothesize that excess IMCL accumulation is dependent on secretory proteins derived from a complex interplay between adipocytes and macrophages in adipose tissue. To test these hypotheses, we will examine the interactions among adipocytes, macrophages, and muscle cells isolated and cultured from subjects that are obese with insulin resistance and impaired glucose tolerance (IGT), and from some with Type 2 Diabetes. This study population has elevated IMCL and is at high risk for obesity complications, but avoids the pathophysiologic complications of glucotoxicity. These subjects will be compared to obese subjects with normal glucose tolerance (NGT). Aim 1 will explore mechanisms that contribute to IMCL and elucidate its role in the development of IGT. Cultured muscle cells will be used to determine whether obese subjects with IGT versus NGT demonstrate intrinsic differences in muscle gene expression and metabolic activity under differing extracellular fatty acid concentrations. Lipid accumulation and oxidation, and insulin-mediated glycogen synthesis and signaling will be assessed. Aim 2 will determine if the IMCL accumulation is dependent on adipose tissue secretory proteins. We will use co-cultures of adipocytes, myoblasts, and adipose stromal vascular cells to examine IMCL and the development of insulin resistance. Aim 3 will determine whether the stromal fraction from IGT subjects promotes IMCL more effectively than that from NGT subjects in co-cultures with muscle cells. We will compare the stromal vascular fractions with regard to monocyte/macrophage accumulation and cytokine expression. Aim 4 will determine if improved glucose tolerance in response to a 10-week treatment with pioglitazone results in decreased IMCL and identify cellular mechanisms involved. Co-culture studies will also be used with muscle and stromal cells, before and after pioglitazone treatment. These experiments will provide mechanistic insight into the link between obesity and muscle function leading to metabolic syndrome.

Interventions

DRUGPioglitazone

Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Philip Kern
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-65 years of age * BMI 28+ * diabetes, impaired glucose tolerance or normal glucose tolerance

Exclusion criteria

* AST \>2x normal * congestive heart failure * history of coronary artery disease * chronic renal insufficiency (creatinine \> 1.4mg/dl) * use of gemfibrozil, ACE inhibitors, and angiotensin receptor II blockers, or anticoagulants

Design outcomes

Primary

MeasureTime frameDescription
Change in Insulin Sensitivity Using FSIGTBaseline and 10 weeksThe frequently sampled intravenous glucose tolerance test (FSIGT) involves the injection of IV glucose and the frequent measurement of glucose and insulin.
Effects of Pioglitazone on Changes in BMIBaseline and 10 weeksBody Mass Index (BMI) is measured at baseline, in lean and obese subjects, and after pioglitazone in obese subjects
Changes in Muscle Lipid After PioglitazoneAt baseline and 10 weeksMuscle lipid following biopsy using oil red-O staining.
Changes in Fat Inflammation Following PioglitazoneBaseline and 10 weeksmacrophages in fat at baseline, in lean and obese participants, and obese after pioglitazone (in obese)

Countries

United States

Participant flow

Participants by arm

ArmCount
Lean Subjects
Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate.
60
Obese Subjects
Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.
10
Total70

Baseline characteristics

CharacteristicObese SubjectsLean SubjectsTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
10 Participants60 Participants70 Participants
Age, Continuous57 years
STANDARD_DEVIATION 2
53 years
STANDARD_DEVIATION 6
55 years
STANDARD_DEVIATION 5
Region of Enrollment
United States
10 participants60 participants70 participants
Sex: Female, Male
Female
7 Participants45 Participants52 Participants
Sex: Female, Male
Male
3 Participants15 Participants18 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 600 / 10
serious
Total, serious adverse events
0 / 600 / 10

Outcome results

Primary

Change in Insulin Sensitivity Using FSIGT

The frequently sampled intravenous glucose tolerance test (FSIGT) involves the injection of IV glucose and the frequent measurement of glucose and insulin.

Time frame: Baseline and 10 weeks

ArmMeasureValue (MEAN)Dispersion
Obese Subjects, BaselineChange in Insulin Sensitivity Using FSIGT1.7 FSIGT units (x10^-4/min/uU/ml)Standard Deviation 0.53
After PioiglitazoneChange in Insulin Sensitivity Using FSIGT2.4 FSIGT units (x10^-4/min/uU/ml)Standard Deviation 1.01
Lean Subjects, BaselineChange in Insulin Sensitivity Using FSIGT7.02 FSIGT units (x10^-4/min/uU/ml)Standard Deviation 3.7
Primary

Changes in Fat Inflammation Following Pioglitazone

macrophages in fat at baseline, in lean and obese participants, and obese after pioglitazone (in obese)

Time frame: Baseline and 10 weeks

ArmMeasureValue (MEAN)Dispersion
Obese Subjects, BaselineChanges in Fat Inflammation Following Pioglitazone27 macrophages per mm2 by CD68 stainingStandard Deviation 6.3
After PioiglitazoneChanges in Fat Inflammation Following Pioglitazone19 macrophages per mm2 by CD68 stainingStandard Deviation 9.5
Lean Subjects, BaselineChanges in Fat Inflammation Following Pioglitazone17 macrophages per mm2 by CD68 stainingStandard Deviation 6.2
Primary

Changes in Muscle Lipid After Pioglitazone

Muscle lipid following biopsy using oil red-O staining.

Time frame: At baseline and 10 weeks

ArmMeasureValue (MEAN)Dispersion
Obese Subjects, BaselineChanges in Muscle Lipid After Pioglitazone7.0 arbitrary units of oil red O stainingStandard Deviation 5.9
After PioiglitazoneChanges in Muscle Lipid After Pioglitazone4.6 arbitrary units of oil red O stainingStandard Deviation 5.9
Lean Subjects, BaselineChanges in Muscle Lipid After Pioglitazone2.7 arbitrary units of oil red O stainingStandard Deviation 0.84
Primary

Effects of Pioglitazone on Changes in BMI

Body Mass Index (BMI) is measured at baseline, in lean and obese subjects, and after pioglitazone in obese subjects

Time frame: Baseline and 10 weeks

ArmMeasureValue (MEAN)Dispersion
Obese Subjects, BaselineEffects of Pioglitazone on Changes in BMI32.4 kg/m2Standard Deviation 3.89
After PioiglitazoneEffects of Pioglitazone on Changes in BMI33.4 kg/m2Standard Deviation 4.36
Lean Subjects, BaselineEffects of Pioglitazone on Changes in BMI22.6 kg/m2Standard Deviation 1.9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026